A Pilot Study to Investigate the Clinical Utility of the Peregrine Monte Carlo Dose Calculation System for Radiation Therapy Treatment Planning

Completed · Phase 2

Conditions studied: Neoplasm

In brief

The utility of PEREGRINE Monte Carlo calculations for radiation treatment planning in a clinical setting will be assessed by comparing results with other fully three-dimensional programs. ROB will investigate PEREGRINE for clinical use at NCI in collaboration with Lawrence Livermore National Laboratory (LLNL).

Key facts

Study ID

NCT00026936

Run by

National Cancer Institute (NCI)

People needed

140

Starts

1999-05-01

Expected to finish

2005-01-01

Last updated by the study team

2008-03-04

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with documented malignancy requiring standard radiotherapy OR patients with a benign condition for whom radiotherapy is indicated.

You may not qualify if…

• Documented connective tissue disease or Ataxia Telangiectasia.
• Cognitively impaired patients who cannot give informed consent.
• Other medical conditions deemed by the PI to make the patient ineligible.
• Patients requiring emergent radiotherapy.
• Patients who are not able to undergo a CT scan.

Where it is running

• National Cancer Institute (NCI) — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.